DS
PTGX icon

David Shaw’s Protagonist Therapeutics PTGX Stock Holding History

David Shaw’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-47,361
Closed -$2.29M – 4650
2025
Q1 		$2.29M Buy
47,361
+41,657
+730% +$1.75M ﹤0.01% 2504
2024
Q4 		$220K Sell
5,704
-21,121
-79% -$921K ﹤0.01% 4046
2024
Q3 		$1.21M Buy
26,825
+13,673
+104% +$552K ﹤0.01% 3127
2024
Q2 		$456K Sell
13,152
-22,488
-63% -$659K ﹤0.01% 3681
2024
Q1 		$1.03M Buy
+35,640
New +$970K ﹤0.01% 3074
2023
Q3 		– Sell
-72,686
Closed -$2.01M – 4438
2023
Q2 		$2.01M Sell
72,686
-126,830
-64% -$3.17M ﹤0.01% 2619
2023
Q1 		$4.59M Buy
199,516
+11,480
+6% +$193K ﹤0.01% 2005
2022
Q4 		$2.05M Buy
188,036
+44,961
+31% +$379K ﹤0.01% 2926
2022
Q3 		$1.21M Buy
+143,075
New +$1.35M ﹤0.01% 3451
2022
Q1 		– Sell
-43,286
Closed -$1.48M – 5854
2021
Q4 		$1.48M Sell
43,286
-72,627
-63% -$2.3M ﹤0.01% 3616
2021
Q3 		$2.05M Sell
115,913
-132,322
-53% -$5.64M ﹤0.01% 3016
2021
Q2 		$11.1M Buy
248,235
+47,255
+24% +$1.56M 0.01% 1406
2021
Q1 		$5.21M Sell
200,980
-135,876
-40% -$3.44M 0.01% 1812
2020
Q4 		$6.79M Sell
336,856
-190,977
-36% -$4.11M 0.01% 1641
2020
Q3 		$10.3M Sell
527,833
-285,113
-35% -$5.35M 0.01% 1225
2020
Q2 		$14.4M Buy
812,946
+532,412
+190% +$6.68M 0.02% 972
2020
Q1 		$1.98M Sell
280,534
-149,983
-35% -$1.12M ﹤0.01% 2179
2019
Q4 		$3.04M Buy
430,517
+100,348
+30% +$997K ﹤0.01% 2141
2019
Q3 		$3.97M Sell
330,169
-67,109
-17% -$846K ﹤0.01% 1827
2019
Q2 		$4.81M Buy
397,278
+139,550
+54% +$1.54M 0.01% 1616
2019
Q1 		$3.24M Buy
257,728
+238,083
+1,212% +$2.1M ﹤0.01% 1828
2018
Q4 		$132K Buy
19,645
+8,450
+75% +$67K ﹤0.01% 3612
2018
Q3 		$115K Sell
11,195
-39,066
-78% -$336K ﹤0.01% 3612
2018
Q2 		$337K Buy
+50,261
New +$386K ﹤0.01% 3319
2018
Q1 		– Sell
-31,251
Closed -$650K – 3736
2017
Q4 		$650K Buy
+31,251
New +$554K ﹤0.01% 2827

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's PTGX Position: Q2 2025 in Review

David Shaw sold out of Protagonist Therapeutics (PTGX) in Q2 2025, closing a stake of 47,361 shares — an estimated $2.29M sold.

David Shaw first reported a position in PTGX in Q4 2017 and held it in 25 quarters. The position peaked at $14.4M in Q2 2020. 273 funds tracked by Wall St. Rank hold PTGX as of Q2 2025.

  • David Shaw reported no remaining Protagonist Therapeutics position as of Q2 2025 after selling out during the quarter.
  • David Shaw sold 47,361 Protagonist Therapeutics shares in Q2 2025, an estimated $2.29M.
  • David Shaw first reported a position in Protagonist Therapeutics in Q4 2017 and held it in 25 quarters.
  • David Shaw's Protagonist Therapeutics position peaked at $14.4M in Q2 2020.
  • 273 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2025.

Based on D.E. Shaw & Co's 13F filing for Q2 2025, filed 14 Aug 2025.